Non-Coding RNAs in Preeclampsia—Molecular Mechanisms and Diagnostic Potential

Munjas, Jelena; Sopić, Miron; Stefanović, Aleksandra; Košir, Rok; Ninić, Ana; Joksić, Ivana; Antonić, Tamara; Spasojević‐Kalimanovska, Vesna; Zmrzljak, Uršula Prosenc

doi:10.3390/ijms221910652

Cited by 34 publications

(27 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PE is defined by severe placental malfunction resulting from invasion, dysregulation, and ultimately remodeling of the spiral arteries of trophoblast differentiation. Disruptions in placentation have serious implications later in pregnancy, leading to a widespread inflammatory response that has a negative influence on maternal and foetal health [ 17 ] .…”

Section: Disscussionmentioning

confidence: 99%

Study the relationship between long non-coding RNA (CCAT1) expression and CDK4 expression levels in Egyptian patients with preeclampsia

Gayed

Shady

Elhelbawy

et al. 2022

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

Section: Disscussionmentioning

confidence: 99%

Study the relationship between long non-coding RNA (CCAT1) expression and CDK4 expression levels in Egyptian patients with preeclampsia

Gayed

Shady

Elhelbawy

et al. 2022

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

“…Blood sampling is less invasive for the mother. Although many ncRNAs have been reported as candidate predictors of PE, most have been analyzed for their expression in the placenta and maternal blood of post-onset PE and week-adjusted control pregnant women [ 36 , 37 , 38 , 39 , 40 , 41 ]. However, ncRNA expression levels in the placenta and maternal blood after the onset of PE may reflect systemic vascular endothelial dysfunction rather than the pathogenesis or cause of PE.…”

Section: Introductionmentioning

confidence: 99%

Non-Coding RNAs and Prediction of Preeclampsia in the First Trimester of Pregnancy

Ogoyama

Takahashi

Suzuki

et al. 2022

Cells

View full text Add to dashboard Cite

Preeclampsia (PE) is a major cause of maternal and perinatal morbidity and mortality. The only fundamental treatment for PE is the termination of pregnancy. Therefore, not only severe maternal complications but also perinatal complications due to immaturity of the infant associated with early delivery are serious issues. The treatment and prevention of preterm onset preeclampsia (POPE) are challenging. In 2017, the ASPRE trial showed that a low oral dose of aspirin administered to POPE high-risk women in early pregnancy reduced POPE by 62%. A prediction algorithm at 11–13 weeks of gestation identifies POPE with 75% sensitivity when the false positive rate is set at 10%. New biomarkers to increase the accuracy of the prediction model for POPE high-risk women in early pregnancy are needed. In this review, we focused on non-coding RNAs (ncRNAs) as potential biomarkers for the prediction of POPE. Highly expressed ncRNAs in the placenta in early pregnancy may play crucial roles in placentation. Furthermore, placenta-specific ncRNAs have been detected in maternal blood. In this review, we summarized ncRNAs that were highly expressed in the primary human placenta in early pregnancy. We also presented highly expressed ncRNAs in the placenta that were associated with or predictive of the development of PE in an expression analysis of maternal blood during the first trimester of pregnancy. These previous studies showed that the chromosome 19 microRNA (miRNA) -derived miRNAs (e.g., miR-517-5p, miR-518b, and miR-520h), the hypoxia-inducible miRNA (miR-210), and long non-coding RNA H19, were not only highly expressed in the early placenta but were also significantly up-regulated in the blood at early gestation in pregnant women who later developed PE. These maternal circulating ncRNAs in early pregnancy are expected to be possible biomarkers for POPE.

show abstract

“…It is possible to provide a hormone-like way for different maternal cells to communicate with each other and even between the mother and the fetus (Xu et al, 2021). Therefore, the differential expressions of miRNAs in maternal circulation can indicate potential placental pathology and can be used as biomarkers for the early detection of pregnancy complications (Zhao et al, 2013;Tian et al, 2020;Munjas et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Integrative analysis of circulating microRNAs and the placental transcriptome in recurrent pregnancy loss

Zhou

Shi

et al. 2022

Front. Physiol.

View full text Add to dashboard Cite

Recurrent pregnancy loss (RPL) is a major type of pathological pregnancy that still lacks reliable early diagnosis and effective treatment. The placenta is critical to fetal development and pregnancy success because it participates in critical processes such as early embryo implantation, vascular remodeling, and immunological tolerance. RPL is associated with abnormalities in the biological behavior of placental villous trophoblasts, resulting in aberrant placental function. MicroRNAs (miRNAs) are increasingly being recognized as essential regulators of placental development, as well as potential biomarkers. In this study, plasma miRNAs and placental messenger RNAs (mRNAs) from RPL patients and normal pregnant (NP) controls were sequenced and analyzed. Compared to those in NP controls, 108 circulating miRNAs and 1199 placental mRNAs were differentially expressed in RPL samples. A total of 140 overlapping genes (overlapping between plasma miRNA target genes and actual placental disorder genes) were identified, and functional enrichment analysis showed that these genes were mainly related to cell proliferation, angiogenesis, and cell migration. The regulatory network among miRNAs, overlapping genes, and downstream biological processes was analyzed by protein–protein interactions and Cytoscape. Moreover, enriched mRNAs, which were predictive targets of the differentially expressed plasma miRNAs miR-766-5p, miR-1285-3p, and miR-520a-3p, were accordingly altered in the placenta. These results suggest that circulating miRNAs may be involved in the pathogenesis of RPL and are potential noninvasive biomarkers for RPL.

show abstract

Non-Coding RNAs in Preeclampsia—Molecular Mechanisms and Diagnostic Potential

Cited by 34 publications

References 150 publications

Study the relationship between long non-coding RNA (CCAT1) expression and CDK4 expression levels in Egyptian patients with preeclampsia

Study the relationship between long non-coding RNA (CCAT1) expression and CDK4 expression levels in Egyptian patients with preeclampsia

Non-Coding RNAs and Prediction of Preeclampsia in the First Trimester of Pregnancy

Integrative analysis of circulating microRNAs and the placental transcriptome in recurrent pregnancy loss

Contact Info

Product

Resources

About